drugset
Drugs / RPESC-RPE-4W
last change Apr 2022 re-read 3 minutes ago

RPESC-RPE-4W

Cell therapy

Developed for
dry age related macular degeneration
Investigated by
California Institute for Regenerative Medicine (CIRM) · Luxa Biotechnology, LLC · National Eye Institute (NEI) · National Institutes of Health (NIH) · Regenerative Research Foundation

Trials 1

today NCT04627428 · Ph 1/2
20232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT04627428 Apr 2022 → Dec 2026 expected dry age related macular degeneration Luxa Biotechnology, LLC Recruiting No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as RPESC-RPE-4W ClinicalTrials.gov intervention name — accepted as the source's own label NCT04627428 ↗
Modality Cell therapy “Allogeneic RPE stem cell (RPESC)-derived RPE cells (RPESC-RPE)” NCT04627428 ↗
Route Other “transplanted under the macular” NCT04627428 ↗